Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 12, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
ErythroplakiaOral Leukoplakia
Interventions
PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Correlative studies

DRUG

Extended Release Metformin Hydrochloride

Given PO

DRUG

Placebo Administration

Given PO

Trial Locations (10)

10010

NYU College of Dentistry, New York

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

33612

Moffitt Cancer Center, Tampa

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

70503

Louisiana State University, Lafayette

85719

University of Arizona Cancer Center-North Campus, Tucson

92103

UC San Diego Medical Center - Hillcrest, San Diego

V5Z 4E6

British Columbia Cancer Agency, Vancouver

B3H 4R2

Dalhousie University, Halifax

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Arizona

OTHER